Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
Titel:
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
Auteur:
Rimassa, Lorenza Assenat, Eric Peck-Radosavljevic, Markus Pracht, Marc Zagonel, Vittorina Mathurin, Philippe Rota Caremoli, Elena Porta, Camillo Daniele, Bruno Bolondi, Luigi Mazzaferro, Vincenzo Harris, William Damjanov, Nevena Pastorelli, Davide Reig, María Knox, Jennifer Negri, Francesca Trojan, Jörg López López, Carlos Personeni, Nicola Decaens, Thomas Dupuy, Marie Sieghart, Wolfgang Abbadessa, Giovanni Schwartz, Brian Lamar, Maria Goldberg, Terri Shuster, Dale Santoro, Armando Bruix, Jordi